Biotech and Life Sciences Patents: Special Considerations

Read what follows with one distinction in mind. Life science patenting fails at a different point from patenting in most other fields: rarely at novelty, frequently at eligibility, and increasingly at the sufficiency of the disclosure supporting a broad claim.

Biotechnology and life sciences represent one of the most intellectually demanding and legally complex areas of patent law. The intersection of cutting-edge science, evolving judicial doctrine, and intense commercial stakes creates an environment where patent strategy decisions made early in the research and development process can determine whether a company captures or cedes its competitive advantage. Unlike software or mechanical inventions, biotechnology inventions must navigate a thicket of unique legal challenges: the product-of-nature doctrine that limits patent eligibility for biological materials, the written description and enablement requirements that demand extraordinary specificity, and the regulatory pathways — FDA approval for drugs and biologics, 510(k) or PMA for medical devices — that create additional layers of market exclusivity beyond patents.

At PerspireIP, we work with biotechnology companies, pharmaceutical firms, research universities, and life sciences startups to build patent portfolios that withstand legal challenge and provide meaningful commercial protection. This guide explains the special considerations that distinguish life sciences patent strategy from other technology domains, covering patentability, prosecution, portfolio management, and the litigation dynamics unique to this field.

Patent Eligibility in Biotechnology: Post-Mayo and Myriad Landscape

The Supreme Court’s decisions in Mayo Collaborative Services v. Prometheus Laboratories (2012) and Association for Molecular Pathology v. Myriad Genetics (2013) fundamentally reshaped patent eligibility doctrine for life sciences inventions. Mayo held that patent claims directed to natural laws — including correlations between drug metabolite levels and therapeutic response — are not patent-eligible under 35 U.S.C. § 101. Myriad held that naturally occurring DNA sequences, including isolated genomic DNA, are products of nature and therefore not patentable, though complementary DNA (cDNA) that does not occur naturally remains eligible. These decisions created massive uncertainty across the life sciences patent landscape that persists today.

Diagnostic claims — particularly those claiming methods of detecting biomarkers, correlating test results with disease states, or selecting treatments based on patient characteristics — have faced intense eligibility challenges. Sophisticated biotech patent prosecution requires crafting claims that navigate these eligibility constraints while preserving meaningful commercial scope. This often means claiming the technical implementation of a diagnostic method — the specific assay steps, the particular reagents, the novel measurement techniques — rather than the underlying natural correlation, which Mayo placed off-limits.

Written Description and Enablement: The Biological Disclosure Burden

In biotechnology, the written description and enablement requirements of 35 U.S.C. § 112 are especially demanding, and they have recently become more stringent. The Federal Circuit’s Amgen v. Sanofi decision — affirmed by the Supreme Court in 2023 — invalidated Amgen’s broad genus claims covering monoclonal antibodies based on functional characteristics, holding that claims covering a vast functional genus of antibodies were not enabled by a disclosure that described only specific examples within the genus. This decision has profound implications for all biotech patent applicants: broad functional claims covering biological molecules must be supported by disclosure that enables a person skilled in the art to make and use substantially all members of the claimed genus without undue experimentation.

For antibody patents, small molecule patents, enzyme patents, and gene therapy patents, this means that patent specifications must provide substantially broader exemplification than was historically required. The written description requirement separately requires that the specification demonstrate that the applicant had possession of the full scope of the claimed invention at the filing date. For functional genus claims in biotechnology, this requires description of representative species spanning the breadth of the genus.

Pharmaceutical Patents: Orange Book Strategy and Hatch-Waxman Litigation

Pharmaceutical patent strategy is uniquely shaped by the Hatch-Waxman Act framework, which governs the approval of generic drugs and creates a structured patent challenge mechanism. Brand-name pharmaceutical companies list patents covering their approved drugs in the FDA’s Orange Book — a public registry of patents associated with approved drug products. These listed patents receive automatic 30-month stays of generic approval when a generic applicant files a Paragraph IV certification challenging their validity or asserting non-infringement.

Effective pharmaceutical patent strategy requires identifying all patentable aspects of a drug product — the active compound, the salt and polymorph forms, the formulation, the method of treatment, the method of manufacture, and the dosing regimen — and securing patents in each category with staggered expiration dates that maximize the exclusivity period.

Generic manufacturers challenge these patents through Paragraph IV certifications and IPR petitions, often attacking the validity of formulation and method-of-use patents that they argue cover incremental rather than truly inventive improvements.

Biologics and Biosimilar Patent Litigation

The Biologics Price Competition and Innovation Act (BPCIA) created a separate regulatory and litigation pathway for biological drugs (biologics) and their follow-on competitors (biosimilars), analogous to the Hatch-Waxman framework for small molecule drugs. The BPCIA’s patent dance — a complex information exchange and litigation notice procedure — governs how reference product sponsors and biosimilar applicants identify and resolve patent disputes before biosimilar market entry. Unlike Hatch-Waxman ANDA litigation, BPCIA patent disputes involve patents covering incredibly complex biological molecules — monoclonal antibodies, fusion proteins, recombinant hormones — and their manufacture in living cell systems.

Patent claims covering manufacturing processes, cell culture conditions, purification methods, and formulation are often as commercially important as claims covering the biologic molecule itself. PerspireIP’s life sciences team has deep experience in BPCIA litigation support, including prior art searches targeting manufacturing process patents, claim charting for biologic product claims, and technical expert support for clinical pharmacology and manufacturing process analysis.

University and Research Institution Technology Transfer

Universities and research institutions generate enormous volumes of patentable biotechnology research, much of it funded by NIH grants and subject to the Bayh-Dole Act framework governing federally funded inventions. Effective technology transfer — the process of licensing university inventions to commercial partners who can develop them into marketable products — requires sophisticated patent strategy that balances the university’s mission of public benefit with the commercial partner’s need for adequate exclusivity to justify development investment. Technology transfer offices face unique challenges: inventions are often disclosed late in the research process, sometimes after publication that may create prior art problems; inventors are frequently focused on scientific recognition rather than commercial application.

Despite these challenges, university biotech patents have produced some of the most commercially valuable technologies in history — from recombinant DNA technology to CRISPR gene editing to CAR-T cell therapy. Building a strong university patent portfolio requires early invention disclosure programs and prosecution strategies that anticipate commercial development pathways.

Life Science Patenting After Amgen v. Sanofi

The most consequential recent development for biotech claim drafting is the Supreme Court’s unanimous decision in Amgen Inc. v. Sanofi, 598 U.S. 594 (2023). Amgen held patents claiming a genus of monoclonal antibodies defined not by their structure but by what they do — binding to a particular region of the PCSK9 protein and blocking it from binding LDL receptors.

The genus potentially spanned millions of antibodies. The specification identified twenty-six by amino-acid sequence and described two methods by which a skilled artisan could purportedly find others with the same functional properties. Writing for a unanimous Court, Justice Gorsuch held the claims were not enabled under 35 U.S.C. § 112(a): the disclosed techniques amounted to a research assignment rather than a description of how to make and use the full scope claimed, and the remainder of the genus could be reached only through painstaking experimentation.

The governing principle the Court restated is short: the more one claims, the more one must enable. The USPTO issued guidelines in January 2024 for assessing enablement in view of the decision, confirming that examiners apply the existing framework rather than a new biotech-specific test.

For practitioners the effect on life science patenting is concrete. Purely functional genus claims to antibodies are now very difficult to sustain. Portfolios are being built instead around sequence-defined claims to the lead molecule and its close variants, claims tied to defined structural features such as CDR sequences, and separate claims to the method of treatment — accepting narrower individual claims in exchange for a set that survives.

What Makes Life Science Patenting Structurally Different

Three features of the sector make it behave unlike mechanical or software patenting, and they compound each other.

The first is unpredictability. Patent law treats the biological arts as unpredictable, which raises the quantum of disclosure needed to support a broad claim. A mechanical engineer can extrapolate from one worked embodiment; the same extrapolation across a class of biological molecules is precisely what Amgen refused to allow. In practice this means more working examples, more data, and a specification that supports each claimed variation rather than gesturing at it.

The second is the mismatch between patent term and development timeline. A patent filed at the point of discovery may have only a few years of term left by the time a therapeutic reaches market after clinical trials and regulatory review. Patent term extension exists to offset part of the regulatory delay, but it is partial and it applies to one patent per approved product. This is why filing strategy in the sector is inseparable from development timing: file too early and the term erodes before revenue; file too late and an intervening publication or a competitor’s application takes priority.

The third is the publication culture. Academic and clinical incentives push toward early disclosure — conference abstracts, preprints, trial registry entries — and any of these can become prior art against the inventor’s own later filing. Where the work originates in a university or a hospital, the practical control is a disclosure protocol agreed with the researchers before submission, not after.

Taken together, these mean life science patenting rewards front-loaded work: more data before filing, a claim set planned across the family rather than drafted claim by claim, and a filing date chosen deliberately against the development plan.

Building a Claim Set That Survives Both Offices

Most life science portfolios of any value are prosecuted on both sides of the Atlantic, and the two systems fail claims for different reasons. Planning for one and adapting later is more expensive than drafting for both from the start.

• Eligibility is a US problem. Natural products, correlations and diagnostic correlations face a subject-matter analysis at the USPTO that has no direct European equivalent. The EPO handles the same territory largely through novelty, inventive step and the exclusions in the European Patent Convention.
• Added matter is a European problem. The EPO applies a strict standard to amendments, so a claim limitation not clearly and unambiguously derivable from the application as filed cannot be introduced later. Intermediate fallback positions therefore have to be written into the specification at drafting, because they cannot be invented during prosecution.
• Methods of treatment diverge. These are claimable in the United States but excluded as such in Europe, where the equivalent protection is obtained through purpose-limited product claims. The same disclosure needs both formats drafted for it.
• Sequence listings are formal requirements. Both offices require sequence data in the prescribed electronic standard, and a defective listing is a formality objection that consumes prosecution time for no substantive reason.

The practical output is a specification written wider than any single jurisdiction needs: multiple levels of generality for each key limitation, worked examples supporting each level, and both claim formats present from the priority filing. That is more drafting effort up front, and it is the difference between a family that can be steered through two examination systems and one that gets stuck in the second.

Frequently Asked Questions

Can you patent a gene sequence or naturally occurring protein?

After Myriad Genetics, naturally occurring DNA sequences — including isolated genomic DNA — are not patent-eligible. However, cDNA (complementary DNA synthesized from mRNA) that does not occur naturally in that form remains patentable. Proteins that are isolated and purified in forms not occurring in nature may retain some eligibility, though post-Mayo analysis applies. The key question is whether the claimed molecule is truly different from what exists in nature, not merely isolated from it. Engineered proteins, modified nucleotides, and synthetic biology constructs with non-natural characteristics typically remain patent-eligible.

How does FDA regulatory exclusivity interact with patent protection?

FDA regulatory exclusivity and patent protection are independent but complementary. Regulatory exclusivity — such as the five-year new chemical entity exclusivity for new drugs, seven-year orphan drug exclusivity, or twelve-year biologic exclusivity — prevents generic or biosimilar approval for a defined period regardless of patent status. Patents can provide additional exclusivity extending well beyond regulatory periods. The interaction between these two systems requires coordinated strategy: companies should time patent filings and regulatory submissions to maximize the combined exclusivity window.

What is the significance of the Amgen v. Sanofi decision for antibody patents?

The Supreme Court’s 2023 Amgen v. Sanofi decision unanimously held that Amgen’s broad functional antibody claims were invalid for lack of enablement. Claims covering all antibodies that bind a specific protein epitope and block its function — without structurally characterizing the antibodies — were not enabled because the specification only described a fraction of the claimed genus. This decision requires antibody patent applicants to provide substantially broader exemplification or to use structurally defined claims rather than functional genus claims. Existing antibody patents with broad functional claims face increased invalidity risk.

How long does biotech patent prosecution typically take?

Biotech patent prosecution is typically longer than prosecution in other technology areas due to the complexity of the subject matter and the frequency of § 101 and § 112 rejections. Average prosecution time from filing to grant in the biotech and pharmaceutical art units runs three to five years. Companies with commercially critical inventions often pursue accelerated examination through programs like Track One prioritized examination, which can reduce prosecution time to twelve months, at additional cost. Continuation applications extend prosecution strategically, allowing claim refinement as the competitive landscape evolves.

What is the Bayh-Dole Act and how does it affect biotech patent ownership?

The Bayh-Dole Act of 1980 governs ownership of inventions made with federal funding. Under Bayh-Dole, universities, small businesses, and non-profits that receive federal research grants may elect to retain ownership of resulting inventions, subject to government license rights and obligations to commercialize the technology. Inventors at federally funded institutions must promptly disclose inventions, and institutions that elect title must file patent applications and make good-faith efforts to commercialize the technology. Commercial licensees of Bayh-Dole inventions must generally manufacture products in the United States unless a waiver is obtained.

Related Reading

• Life Science Patents: 6 Essential Rules to Protect R&D
• Claim Construction: 6 Keys to Winning a Markman Hearing
• Patent drawing services — flat $25 per figure, USPTO and EPO compliant.
• 37 CFR 1.84: the full USPTO drawing standard
• Design patent drawings: required views and broken lines
• USPTO — official text of 37 CFR 1.84